Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Philip Ferneau is Director at Compass Therapeutics. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jan 5, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
Jan 2, 202690Kdisclosed Jan 5
DetailsOfficial recordPhilip Ferneau reported 2 open-market purchases and 0 sales here, 2020.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
Philip Ferneau bought shares on the open market in 2020, and has not bought since 2020.
In SEC filings since 2020: the latest open-market purchase is from 2020; no open-market sale is on record.
Compass Therapeutics (CMPX), from 2020 to 2020: 2 purchases and 0 sales.
Philip Ferneau bought shares on the open market in 2020, and has not bought since 2020.
Philip Ferneau reported 2 open-market purchases and 0 sales since 2020; purchases in 2020.
| Year | Bought | Sold |
|---|---|---|
| 2020 | $1.57M2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.